-
1
-
-
70350449256
-
New advances in the management of juvenile idiopathic arthritis-2: The era of biologicals
-
Beresford MW, Baildam EM,. New advances in the management of juvenile idiopathic arthritis-2: the era of biologicals. Arch Dis Child Educ Pract Ed 2009; 94: 151-6.
-
(2009)
Arch Dis Child Educ Pract Ed
, vol.94
, pp. 151-156
-
-
Beresford, M.W.1
Baildam, E.M.2
-
2
-
-
4544363019
-
Biological therapies in the spondyloarthritides: The current state
-
Braun J, Sieper J,. Biological therapies in the spondyloarthritides: the current state. Rheumatology (Oxford) 2004; 43: 1072-84.
-
(2004)
Rheumatology (Oxford)
, vol.43
, pp. 1072-1084
-
-
Braun, J.1
Sieper, J.2
-
3
-
-
2442590862
-
New drugs for rheumatoid arthritis
-
Olsen NJ, Stein CM,. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350: 2167-79.
-
(2004)
N Engl J Med
, vol.350
, pp. 2167-2179
-
-
Olsen, N.J.1
Stein, C.M.2
-
4
-
-
78649477259
-
TNF-α antagonists beyond approved indications: Stories of success and prospects for the future
-
Karampetsou MP, Liossis SN, Sfikakis PP,. TNF-α antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010; 103: 917-28.
-
(2010)
QJM
, vol.103
, pp. 917-928
-
-
Karampetsou, M.P.1
Liossis, S.N.2
Sfikakis, P.P.3
-
5
-
-
84862610971
-
Infections in patients with rheumatic diseases treated with TNF antagonists
-
Perez-Zafrilla B, Carmona L, Gomez-Reino JJ,. Infections in patients with rheumatic diseases treated with TNF antagonists. Curr Pharm Biotechnol 2012; 13: 1418-25.
-
(2012)
Curr Pharm Biotechnol
, vol.13
, pp. 1418-1425
-
-
Perez-Zafrilla, B.1
Carmona, L.2
Gomez-Reino, J.J.3
-
6
-
-
27744499707
-
Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors
-
Chakravarty EF, Michaud K, Wolfe F,. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32: 2130-5.
-
(2005)
J Rheumatol
, vol.32
, pp. 2130-2135
-
-
Chakravarty, E.F.1
Michaud, K.2
Wolfe, F.3
-
7
-
-
23644447586
-
Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction
-
Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A,. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005; 52: 2513-8.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 2513-2518
-
-
Sfikakis, P.P.1
Iliopoulos, A.2
Elezoglou, A.3
Kittas, C.4
Stratigos, A.5
-
8
-
-
58849160468
-
Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register
-
Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68: 209-15.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 209-215
-
-
Harrison, M.J.1
Dixon, W.G.2
Watson, K.D.3
King, Y.4
Groves, R.5
Hyrich, K.L.6
-
9
-
-
72949116745
-
Development of alopecia areata after biological therapy with TNF-α blockers: Description of a case and review of the literature
-
Hernandez MV, Nogues S, Ruiz-Esquide V, Alsina M, Canete JD, Sanmarti R,. Development of alopecia areata after biological therapy with TNF-α blockers: description of a case and review of the literature. Clin Exp Rheumatol 2009; 27: 892-3.
-
(2009)
Clin Exp Rheumatol
, vol.27
, pp. 892-893
-
-
Hernandez, M.V.1
Nogues, S.2
Ruiz-Esquide, V.3
Alsina, M.4
Canete, J.D.5
Sanmarti, R.6
-
10
-
-
84855717578
-
Relapsing polychondritis: A new adverse event secondary to the use of tumour necrosis factor antagonists?
-
Hernandez MV, Ruiz-Esquide V, Gomez-Caballero ME, Gomez-Puerta JA, Canete JD, Sanmarti R,. Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists? Rheumatology (Oxford) 2011; 50: 1523-5.
-
(2011)
Rheumatology (Oxford)
, vol.50
, pp. 1523-1525
-
-
Hernandez, M.V.1
Ruiz-Esquide, V.2
Gomez-Caballero, M.E.3
Gomez-Puerta, J.A.4
Canete, J.D.5
Sanmarti, R.6
-
11
-
-
84865389552
-
Morphea associated with the use of adalimumab: A case report and review of the literature
-
Ramirez J, Hernandez MV, Galve J, Canete JD, Sanmarti R,. Morphea associated with the use of adalimumab: a case report and review of the literature. Mod Rheumatol 2012; 22: 602-4.
-
(2012)
Mod Rheumatol
, vol.22
, pp. 602-604
-
-
Ramirez, J.1
Hernandez, M.V.2
Galve, J.3
Canete, J.D.4
Sanmarti, R.5
-
13
-
-
79951719602
-
Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: Data from the Spanish registry BIOBADASER 2.0
-
Carmona L, Descalzo MA, Ruiz-Montesinos D, Manero-Ruiz FJ, Perez-Pampin E, Gomez-Reino JJ, et al. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology (Oxford) 2011; 50: 85-92.
-
(2011)
Rheumatology (Oxford)
, vol.50
, pp. 85-92
-
-
Carmona, L.1
Descalzo, M.A.2
Ruiz-Montesinos, D.3
Manero-Ruiz, F.J.4
Perez-Pampin, E.5
Gomez-Reino, J.J.6
-
14
-
-
2342658406
-
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial
-
Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 1400-1411
-
-
Keystone, E.C.1
Kavanaugh, A.F.2
Sharp, J.T.3
Tannenbaum, H.4
Hua, Y.5
Teoh, L.S.6
-
15
-
-
0031660364
-
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
-
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
-
(1998)
Arthritis Rheum
, vol.41
, pp. 1552-1563
-
-
Maini, R.N.1
Breedveld, F.C.2
Kalden, J.R.3
Smolen, J.S.4
Davis, D.5
Macfarlane, J.D.6
-
16
-
-
0033611472
-
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
-
Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
-
(1999)
N Engl J Med
, vol.340
, pp. 253-259
-
-
Weinblatt, M.E.1
Kremer, J.M.2
Bankhurst, A.D.3
Bulpitt, K.J.4
Fleischmann, R.M.5
Fox, R.I.6
-
17
-
-
74149087430
-
Cutaneous events during anti-TNF α therapy: A prospective observational study of 41 cases
-
In French
-
Bonnet N, Guis S, Koeppel MC, Roudier J, Grimaud JC, Jean-Pastor MJ, et al. Cutaneous events during anti-TNF α therapy: a prospective observational study of 41 cases. Ann Dermatol Venereol 2010; 137: 12-20. In French.
-
(2010)
Ann Dermatol Venereol
, vol.137
, pp. 12-20
-
-
Bonnet, N.1
Guis, S.2
Koeppel, M.C.3
Roudier, J.4
Grimaud, J.C.5
Jean-Pastor, M.J.6
-
18
-
-
70350049105
-
Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor α inhibitors
-
Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA,. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor α inhibitors. Scand J Rheumatol 2009; 38: 328-31.
-
(2009)
Scand J Rheumatol
, vol.38
, pp. 328-331
-
-
Exarchou, S.A.1
Voulgari, P.V.2
Markatseli, T.E.3
Zioga, A.4
Drosos, A.A.5
-
19
-
-
24944532440
-
Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: A prospective study
-
Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL,. Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005; 7: R666-76.
-
(2005)
Arthritis Res Ther
, vol.7
-
-
Flendrie, M.1
Vissers, W.H.2
Creemers, M.C.3
De Jong, E.M.4
Van De Kerkhof, P.C.5
Van Riel, P.L.6
-
20
-
-
33846950349
-
Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-α antagonists
-
Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-α antagonists. Br J Dermatol 2007; 156: 486-91.
-
(2007)
Br J Dermatol
, vol.156
, pp. 486-491
-
-
Lee, H.H.1
Song, I.H.2
Friedrich, M.3
Gauliard, A.4
Detert, J.5
Rowert, J.6
-
21
-
-
77957274056
-
Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists
-
Garcia-Doval I, Perez-Zafrilla B, Descalzo MA, Rosello R, Hernandez MV, Gomez-Reino JJ, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010; 69: 1751-5.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 1751-1755
-
-
Garcia-Doval, I.1
Perez-Zafrilla, B.2
Descalzo, M.A.3
Rosello, R.4
Hernandez, M.V.5
Gomez-Reino, J.J.6
-
22
-
-
60749125474
-
Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents
-
Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA 2009; 301: 737-44.
-
(2009)
JAMA
, vol.301
, pp. 737-744
-
-
Strangfeld, A.1
Listing, J.2
Herzer, P.3
Liebhaber, A.4
Rockwitz, K.5
Richter, C.6
-
23
-
-
84872056023
-
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register
-
Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013; 72: 229-34.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 229-234
-
-
Galloway, J.B.1
Mercer, L.K.2
Moseley, A.3
Dixon, W.G.4
Ustianowski, A.P.5
Helbert, M.6
-
24
-
-
33747008410
-
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register
-
British Society for Rheumatology Biologics Register Control Centre Consortium, et al, on behalf of the British Society for Rheumatology Biologics Register.
-
Dixon WG, Watson K, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al, on behalf of the British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 2368-2376
-
-
Dixon, W.G.1
Watson, K.2
Lunt, M.3
Hyrich, K.L.4
Silman, A.J.5
-
25
-
-
27744458586
-
Infections in patients with rheumatoid arthritis treated with biologic agents
-
Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 3403-3412
-
-
Listing, J.1
Strangfeld, A.2
Kary, S.3
Rau, R.4
Von Hinueber, U.5
Stoyanova-Scholz, M.6
-
26
-
-
84874748525
-
Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster
-
Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309: 887-95.
-
(2013)
JAMA
, vol.309
, pp. 887-895
-
-
Winthrop, K.L.1
Baddley, J.W.2
Chen, L.3
Liu, L.4
Grijalva, C.G.5
Delzell, E.6
-
27
-
-
33846657544
-
Infections during tumour necrosis factor-α blocker therapy for rheumatic diseases in daily practice: A systematic retrospective study of 709 patients
-
Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, et al. Infections during tumour necrosis factor-α blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007; 46: 327-34.
-
(2007)
Rheumatology (Oxford)
, vol.46
, pp. 327-334
-
-
Salliot, C.1
Gossec, L.2
Ruyssen-Witrand, A.3
Luc, M.4
Duclos, M.5
Guignard, S.6
-
28
-
-
0025294542
-
Cytokine modulation of keratinocyte cytokines
-
Ansel J, Perry P, Brown J, Damm D, Phan T, Hart C, et al. Cytokine modulation of keratinocyte cytokines. J Invest Dermatol 1990; 94 Suppl: 101S-7S.
-
(1990)
J Invest Dermatol
, vol.94
, Issue.SUPPL.
-
-
Ansel, J.1
Perry, P.2
Brown, J.3
Damm, D.4
Phan, T.5
Hart, C.6
-
29
-
-
70449486874
-
Innate immunity and allergy in the skin
-
Metz M, Maurer M,. Innate immunity and allergy in the skin. Curr Opin Immunol 2009; 21: 687-93.
-
(2009)
Curr Opin Immunol
, vol.21
, pp. 687-693
-
-
Metz, M.1
Maurer, M.2
-
30
-
-
37549005087
-
Tumor necrosis factor-α inhibitor-induced psoriasis or psoriasiform exanthemata: First 120 cases from the literature including a series of six new patients
-
Wollina U, Hansel G, Koch A, Schonlebe J, Kostler E, Haroske G,. Tumor necrosis factor-α inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9: 1-14.
-
(2008)
Am J Clin Dermatol
, vol.9
, pp. 1-14
-
-
Wollina, U.1
Hansel, G.2
Koch, A.3
Schonlebe, J.4
Kostler, E.5
Haroske, G.6
-
31
-
-
78649445740
-
Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis
-
Collamer AN, Battafarano DF,. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40: 233-40.
-
(2010)
Semin Arthritis Rheum
, vol.40
, pp. 233-240
-
-
Collamer, A.N.1
Battafarano, D.F.2
-
32
-
-
4043107880
-
Alopecia areata in a patient using infliximab: New insights into the role of tumor necrosis factor on human hair follicles
-
[letter].
-
Ettefagh L, Nedorost S, Mirmirani P,. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles [letter]. Arch Dermatol 2004; 140: 1012.
-
(2004)
Arch Dermatol
, vol.140
, pp. 1012
-
-
Ettefagh, L.1
Nedorost, S.2
Mirmirani, P.3
-
33
-
-
43049147124
-
Alopecia areata universalis elicited during treatment with adalimumab
-
Pelivani N, Hassan AS, Braathen LR, Hunger RE, Yawalkar N,. Alopecia areata universalis elicited during treatment with adalimumab. Dermatology 2008; 216: 320-3.
-
(2008)
Dermatology
, vol.216
, pp. 320-323
-
-
Pelivani, N.1
Hassan, A.S.2
Braathen, L.R.3
Hunger, R.E.4
Yawalkar, N.5
-
34
-
-
79955003756
-
TNF α antagonist-induced lupus-like syndrome: Report and review of the literature with implications for treatment with alternative TNF α antagonists
-
Williams VL, Cohen PR,. TNF α antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF α antagonists. Int J Dermatol 2011; 50: 619-25.
-
(2011)
Int J Dermatol
, vol.50
, pp. 619-625
-
-
Williams, V.L.1
Cohen, P.R.2
-
35
-
-
84862856646
-
Skin manifestations induced by TNF-α inhibitors in juvenile idiopathic arthritis
-
Pontikaki I, Shahi E, Frasin LA, Gianotti R, Gelmetti C, Gerloni V, et al. Skin manifestations induced by TNF-α inhibitors in juvenile idiopathic arthritis. Clin Rev Allergy Immunol 2012; 42: 131-4.
-
(2012)
Clin Rev Allergy Immunol
, vol.42
, pp. 131-134
-
-
Pontikaki, I.1
Shahi, E.2
Frasin, L.A.3
Gianotti, R.4
Gelmetti, C.5
Gerloni, V.6
-
36
-
-
77952825328
-
Morphea, an unusual side effect of anti-TNF-α treatment
-
[letter]
-
Mattozzi C, Richetta AG, Cantisani C, Giancristoforo S, D'Epiro S, Gonzalez Serva A, et al. Morphea, an unusual side effect of anti-TNF-α treatment [letter]. Eur J Dermatol 2010; 20: 400-1.
-
(2010)
Eur J Dermatol
, vol.20
, pp. 400-401
-
-
Mattozzi, C.1
Richetta, A.G.2
Cantisani, C.3
Giancristoforo, S.4
D'Epiro, S.5
Gonzalez Serva, A.6
-
37
-
-
41849115630
-
Granuloma annulare induced by anti-tumour necrosis factor therapy
-
Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA,. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008; 67: 567-70.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 567-570
-
-
Voulgari, P.V.1
Markatseli, T.E.2
Exarchou, S.A.3
Zioga, A.4
Drosos, A.A.5
-
38
-
-
80051469514
-
Cancer in patients with rheumatic diseases exposed to TNF antagonists
-
Carmona L, Abasolo L, Descalzo MA, Perez-Zafrilla B, Sellas A, de Abajo F, et al. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum 2011; 41: 71-80.
-
(2011)
Semin Arthritis Rheum
, vol.41
, pp. 71-80
-
-
Carmona, L.1
Abasolo, L.2
Descalzo, M.A.3
Perez-Zafrilla, B.4
Sellas, A.5
De Abajo, F.6
-
39
-
-
77956026744
-
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology
-
Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 2010; 69: 1596-602.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 1596-1602
-
-
Dixon, W.G.1
Carmona, L.2
Finckh, A.3
Hetland, M.L.4
Kvien, T.K.5
Landewe, R.6
-
40
-
-
34848893989
-
Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study
-
Wolfe F, Michaud K,. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-95.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 2886-2895
-
-
Wolfe, F.1
Michaud, K.2
-
41
-
-
27744527575
-
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
-
Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-6.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 1421-1426
-
-
Askling, J.1
Fored, C.M.2
Brandt, L.3
Baecklund, E.4
Bertilsson, L.5
Feltelius, N.6
-
42
-
-
80053565309
-
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis
-
Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70: 1895-904.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1895-1904
-
-
Mariette, X.1
Matucci-Cerinic, M.2
Pavelka, K.3
Taylor, P.4
Van Vollenhoven, R.5
Heatley, R.6
-
43
-
-
84868470243
-
Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors
-
Mariette X, Reynolds AV, Emery P,. Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors. Ann Rheum Dis 2012; 71: e2.
-
(2012)
Ann Rheum Dis
, vol.71
-
-
Mariette, X.1
Reynolds, A.V.2
Emery, P.3
-
44
-
-
0032930490
-
Risk factors of non-melanoma skin cancer in United States veterans patients: A pilot study and review of literature
-
Chuang TY, Brashear R,. Risk factors of non-melanoma skin cancer in United States veterans patients: a pilot study and review of literature. J Eur Acad Dermatol Venereol 1999; 12: 126-32.
-
(1999)
J Eur Acad Dermatol Venereol
, vol.12
, pp. 126-132
-
-
Chuang, T.Y.1
Brashear, R.2
-
45
-
-
33750317924
-
Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions
-
Douglas KM, Ladoyanni E, Treharne GJ, Hale ED, Erb N, Kitas GD,. Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions. Ann Rheum Dis 2006; 65: 1341-5.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 1341-1345
-
-
Douglas, K.M.1
Ladoyanni, E.2
Treharne, G.J.3
Hale, E.D.4
Erb, N.5
Kitas, G.D.6
-
46
-
-
84860915531
-
The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: Longitudinal results from the British Society for Rheumatology Biologics Register
-
Mercer LK, Green AC, Galloway JB, Davies R, Lunt M, Dixon WG, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012; 71: 869-74.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 869-874
-
-
Mercer, L.K.1
Green, A.C.2
Galloway, J.B.3
Davies, R.4
Lunt, M.5
Dixon, W.G.6
-
47
-
-
84876303432
-
Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis
-
Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65: 353-61.
-
(2013)
Arthritis Care Res (Hoboken)
, vol.65
, pp. 353-361
-
-
Widdifield, J.1
Bernatsky, S.2
Paterson, J.M.3
Gunraj, N.4
Thorne, J.C.5
Pope, J.6
-
48
-
-
40349092811
-
The epidemiology of glucocorticoid-associated adverse events
-
McDonough AK, Curtis JR, Saag KG,. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008; 20: 131-7.
-
(2008)
Curr Opin Rheumatol
, vol.20
, pp. 131-137
-
-
McDonough, A.K.1
Curtis, J.R.2
Saag, K.G.3
-
49
-
-
0033053835
-
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
-
and the European Leflunomide Study Group
-
Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al, and the European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999; 353: 259-66.
-
(1999)
Lancet
, vol.353
, pp. 259-266
-
-
Smolen, J.S.1
Kalden, J.R.2
Scott, D.L.3
Rozman, B.4
Kvien, T.K.5
Larsen, A.6
-
50
-
-
23444461026
-
Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis
-
Kalden JR, Antoni C, Alvaro-Gracia JM, Combe B, Emery P, Kremer JM, et al. Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J Rheumatol 2005; 32: 1620-31.
-
(2005)
J Rheumatol
, vol.32
, pp. 1620-1631
-
-
Kalden, J.R.1
Antoni, C.2
Alvaro-Gracia, J.M.3
Combe, B.4
Emery, P.5
Kremer, J.M.6
|